

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

**Drug Use Review
Board Meeting Minutes**

Date of Meeting: Thursday, October 20, 2022

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board

Agenda Item	Record	Notes																																	
<p>1. Call to Order and Roll Call</p>	<p>It was announced the meeting is being recorded.</p> <p>Chairperson Wheeler called the meeting to order at 1:04 p.m. on October 20, 2022.</p> <p>Chairperson Wheeler took the roll.</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"></th> <th style="width: 10%; text-align: center;">Present</th> <th style="width: 10%; text-align: center;">Absent</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Michael Owens, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Rebecca Sparks, PA-C</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none"> • Lithier, Gabriel, Senior Deputy Attorney General • Olsen, David, Chief of Pharmacy Services • Gudino, Antonio, Manager of Pharmacy Services • Prada, Vanessa, Social Services Program Specialist (SSPS) II, Managed Care Unit • Berntson, Kindra, SSPS II, Pharmacy Unit • Flowers, Ellen, Program Officer I, Pharmacy Unit <p>Magellan Rx Staff Present were as follows:</p> <ul style="list-style-type: none"> • Mishra, Raj, Pharm.D., Clinical Account Manager • Kim, James, Pharm.D., Dir. Clinical Account Services • Martinez, Chris, Sr. Business Analyst
	Present	Absent																																	
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																																	
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																																	
• Mark Canty, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																	
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																																	
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																	
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																																	
• Brain Le, DO	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																	
• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																																	
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																	
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																																	

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

		<p>Managed Care Organization representatives present were as follows:</p> <ul style="list-style-type: none"> • Lim, Luke, Pharm.D., Anthem • Saunders-Newey, Tiffany, Pharm.D., Anthem • Bitton, Ryan, Pharm.D., Health Plan of Nevada • Beranek, Tom, Pharm.D., Silver Summit Health Plan • Tran, Jimmy, Pharm.D., Molina Healthcare <p>The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.</p>
<p>2. General Public Comment</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Kaysen Bala pharmacist and medical account director with Biogen.</p> <p>Public comment was provided by Deb Profant with jazz pharmaceuticals.</p> <p>Public comment was provided by Kathleen Bailey with Synexus.</p>	
<p>3. Administrative</p>		



<p>a. For Possible Action: Review and Approve Meeting Minutes from July 28, 2022</p>	<p>Board Member Netochi moved to approve the minutes as presented, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Rebecca Sparks, PA-C</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
<p>b. Status Update by DHCFP</p>	<p>Chief of Pharmacy Services David Olsen provided five announcements.</p> <ul style="list-style-type: none"> • Governor Sisolak has announced the launch of Array RX. This is a digital discount card for prescription drugs. All Nevadans should be able to access the free discount card regardless of age or income using the digital card to help save up to 80% on certain medications. The card went live on Monday. The program is not part of Medicaid pharmacy benefit, as Medicaid has an open formulary and drugs that are FDA approved and medically necessary to rebate eligible or covered for beneficiaries. However, there may be cases where beneficiaries purchase drugs for other use, and they would be able to use this discount card. 																																													



	<ul style="list-style-type: none"> • As part of the recent change of pharmacy benefit manager vendor, pharmacy information and related updates are housed at a new website: https://nevadamedicaid.magellanrx.com • Nevada Medicaid is joining the National Medicaid Pooling Initiative (NMPI). Additionally, we're also able to note that we are joining the diabetic supply pool. This change will occur on October 1st of this year. For more information regarding NMPI you can contact two individuals at Magellan Medicaid Administration. They are Eileen Zimmer and her e-mail address is eezimmer@magellanhealth.com and Kristen Haloski and her e-mail is kmhaloski@magellanhealth.com. • Nevada Medicaid has established licensed pharmacists as a new provider type. Services related to dispensing self-administered contraceptives and prescribing HIV prevention medications are now reimbursable when provided by a pharmacist enrolled Nevada Medicaid provider. For more information on how to enroll as a Nevada Medicaid provider, please visit the provider enrollment page that's found at the website www.medicaid.nv.gov. • Nevada Medicaid also hosted a public workshop concerning a project to manage position administer drugs. A list of 60 specialty physician administrated Drugs requiring prior authorization was presented at this workshop. These prior authorizations will not be required until this project is implemented, is tentatively scheduled for the first half of next year. 	
<p>c. Bylaws</p>	<ul style="list-style-type: none"> • We have proposed some changes with the bylaws. I do need to clarify that the board does not approve changes to the bylaws. That responsibility falls to the director. However, we do want to make you aware of several changes and we are open to any feedback regarding any inconsistencies or questions once the 	



	<p>bylaws are approved by the director, we would send out new copies of the bylaw to each board member.</p> <ul style="list-style-type: none"> • Correction of time for public comment. Public comments are limited to 3 minutes. • Clarification regarding the DUR BOARD coordinator position. • we also made a clarification that meetings may be attended electronically. 	
<p>4. Clinical Presentations</p>		
<p>a. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Vivjoa.</p>		
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Raj Mishra discussed the new drug update for VIVJOA (oteseconazole).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of VIVJOA (oteseconazole).</p> <ul style="list-style-type: none"> • Dr. Luke Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Ryan Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Tom Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. 	



	<ul style="list-style-type: none"> Dr. Jimmy Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 																																													
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																													
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Rebecca Sparks, PA-C</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Vonoprazan and amoxicillin (Voquezna™ Dual Pak™).																																														



<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Mishra discussed the new drug update for Vonoprazan and amoxicillin (Voquezna™ Dual Pak™).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Vonoprazan and amoxicillin (Voquezna™ Dual Pak™).</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Casteneda moved to approve the criteria as presented by Magellan, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	



		Yes	No	Abst.	
	<ul style="list-style-type: none"> • Jennifer Wheeler, Pharm.D., Chair • Netochi Adeolokun, Pharm.D., Vice Chair • Mark Canty, MD • Crystal Castaneda, MD • Jessica Cate, Pharm.D. • Dave England, Pharm.D. • Brain Le, DO • Michael Owens, MD • Rebecca Sparks, PA-C • Jim Tran, Pharm.D. 	<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>	
c. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Maribavir (Livtency™).					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>				
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the new drug update for Maribavir (Livtency™).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Maribavir (Livtency™).</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. 				



	<ul style="list-style-type: none"> • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 																																													
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																													
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Owens seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Michael Owens, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Rebecca Sparks, PA-C</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
<p>d. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Trientine</p>																																														



<p>tetrahydrochloride (Cuvrior™).</p>		
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Mishra discussed the Drug Bulletin for Trientine tetrahydrochloride (Cuvrior™).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Trientine tetrahydrochloride (Cuvrior™).</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member Owens seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	



		Yes	No	Abst.	
	<ul style="list-style-type: none"> Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Michael Owens, MD Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>	
e. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Mitapivat (Pyrukynd®).					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>				
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the new drug update for Mitapivat (Pyrukynd®).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Mitapivat (Pyrukynd®).</p> <ul style="list-style-type: none"> Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. 				



	<ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 																																													
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																													
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member England moved to approve the criteria as presented by Magellan, and Board Member Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 80%;"></th> <th style="width: 10%; text-align: center;">Yes</th> <th style="width: 10%; text-align: center;">No</th> <th style="width: 10%; text-align: center;">Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Michael Owens, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Rebecca Sparks, PA-C</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
<p>f. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or</p>																																														



<p>quantity limits for Narcolepsy Agents.</p>		
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Deb Profant from Jazz Pharmaceuticals.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Mishra discussed the new proposed criterial for Provigil® (modafinil), and Nuvigil® (armodafinil).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Provigil® (modafinil), and Nuvigil® (armodafinil).</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Owens moved to approve the criteria as presented by Magellan, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	



		Yes	No	Abst.	
	<ul style="list-style-type: none"> Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Michael Owens, MD Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	<input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>	
g. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Apomorphine (Kynmobi™).					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Jennifer Wilbanks with health economics outcomes research liaison with synovial.</p>				
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the indication for Apomorphine (Kynmobi™).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Apomorphine (Kynmobi™).</p> <ul style="list-style-type: none"> Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. 				



	<ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 																													
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>Board Member Adeolokun comment regarding the PA criteria for trimethylbenzene.</p> <ul style="list-style-type: none"> • Dr. Mishra informed that no PA is required for trimethylbenzene. <p>Board Member Tran comment regarding safety concern regarding QTC prolongation.</p> <ul style="list-style-type: none"> • Dr. Tran was informed that there were no findings of anything on the sublingual exposure for QTC prolongation published. 																													
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="592 1149 1381 1409"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											



	<ul style="list-style-type: none"> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Michael Owens, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
<p>h. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Vutrisiran (Amvuttra™).</p>		
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Sammy Straley with Medical Outcome Science liaison.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Mishra discussed the indication for the new drug update for Vutrisiran (Amvuttra™).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Vutrisiran (Amvuttra™).</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	



<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members. No comments were made.</p>																																													
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Owens moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="590 574 1381 987"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Rebecca Sparks, PA-C</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
<p>i. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Immunomodulators.</p>																																														
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided. No written comment was received.</p>																																													



<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Mishra discussed the proposed changes to criteria for Immunomodulators.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Immunomodulators.</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 																																	
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																	
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member England moved to approve the criteria as presented by Magellan, and Board Member Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															



	<ul style="list-style-type: none"> • Michael Owens, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
j. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Androgenic Agents.		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p> <p>No written comment was received.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the proposed changes to criteria for Androgenic Agents.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Androgenic Agents.</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	



<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																													
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Owens seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="590 610 1381 1019"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Michael Owens, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Rebecca Sparks, PA-C</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Michael Owens, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																											
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																											
<p>k. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Cenegermin-bkbj (Oxervate™).</p>																																														
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																													



<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Mishra discussed the indications for the new drug update for Cenegermin-bkbj (Oxervate™).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Cenegermin-bkbj (Oxervate™).</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 																																	
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																	
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Owens moved to approve the criteria as presented by Magellan, and Board Member Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="590 1117 1381 1411"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Mark Canty, MD</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															



	<ul style="list-style-type: none"> • Michael Owens, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
5. DUR Board Requested Reports		
<p>a. Opioid Reports:</p> <ul style="list-style-type: none"> i. Opioid Trends ii. Count of Claims iii. Med Trend iv. Top Members v. Top Ten Prescribers vi. MED 	<ul style="list-style-type: none"> • Dr. Mishra presented opioid utilization reports. • Dr. Lim presented opioid utilization reports. • Dr. Bitton presented opioid utilization reports. • Dr. Beranek presented opioid utilization reports. • Dr. Tran presented opioid utilization reports. 	
<p>b. Standard DUR Reports:</p> <ul style="list-style-type: none"> i. Top 10 Classes by amount paid ii. By Claim Count iii. cDUR Quarterly Report iv. cDUR Detail Activity Summary v. cDUR Detailed Saving Outcome vi. Retro DUR 	<ul style="list-style-type: none"> • Dr. Mishra presented Standard DUR Reports • Dr. Lim presented Standard DUR Reports. • Dr. Bitton presented Standard DUR Reports • Dr. Beranek presented Standard DUR Reports • Dr. Tran presented Standard DUR Reports. 	
<p>c. 2021 CMS DUR Survey Annual Summary</p>	<ul style="list-style-type: none"> • Dr. Mishra presented FFS annual survey • Dr. Lim presented Anthem annual survey. • Dr. Bitton presented Health Plan of Nevada annual survey. • Dr. Beranek presented Silver Summit annual survey. • Dr. Tran presented Molinas annual survey. 	
6. Closing Discussion		
<p>a. Public Comment</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	

Steve Sisolak
Governor
Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
Division of Health Care Financing and Policy
Helping people. It's who we are and what we do.



Suzanne Bierman, JD, MPH
Administrator

b. For Possible Action: Date and location of the next meeting.	Chairperson Wheeler stated the next meeting is scheduled for January 19, 2023.	
c. Adjournment	The meeting adjourned at 2:56 p.m.	

Attachment A – Members of the Public in Attendance

Trashelle Miro	Karen Ou	Levin, Amy, MD	Lovan, Charlie R
Kevin Hinthorne	Rianna White	Kaysen Bala	Deb Profant
Tyler Shaw	Ken Riddle	Jason C Bott	Wilbanks, Jennifer
Amy Breen Teva	Amy Breen Teva	Michael Zarob	Danielle Addis
Crecco, Jason	Sandy Dervisevic	Hertzberg, Susan	Sami Nasrawi
Kathleen Bailey	Cheryl Donahue	Waring, Ashlee	Rich Dabner
Vanessa Dunn	Colabianchi, Jeana	Yamashita, Kelvin /US	Ann Nelson
Olaf Reinwald	Flagg-Brown, Kimberly A.	Levin, Amy, MD	
Wilbanks, Jennifer	Kevin Hinthorne	Yip, Brandon /US	
Hale, Amy	Gao, Sara Elizabeth	Olaf Reinwald	

Attachment B – Submitted Written Comment

[Epidiolex](#)

[Xywav](#)

[Hepatitis C](#)